Company: BFRG
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023560
Chunk: 75

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Item 2
Chunk 75
---

cancer, and others. We have also signed an exclusive worldwide license from George Washington University for another cancer drug that
targets hepatocellular carcinoma (liver cancer) and other liver diseases. In addition, we signed three-year strategic data and commercialization
agreements with the Lieber Institute for Brain Development (“LIBD”) whom we believe has a repository of the largest collection
of postmortem brains in the world, including molecular, clinical, and other data. The objective of this collaboration with LIBD is for
the Company to analyze these rich data sets using its proprietary AI/ML tools and models and then go to market with the discoveries with
the ultimate goal of securing revenue generating strategic partnership deals with biopharmaceutical companies. We intend to secure the
rights to other proprietary data sets and repeat this strategy. Additionally, we intend to gain access to later-stage clinical assets
through partnerships or the acquisition of rights to failed therapeutic candidates for drug rescue. In certain circumstances, we intend
to conduct late-stage clinical trials in an effort to rescue therapeutic assets that previously failed. In these cases, there will be
a requirement for drug supply and regulatory services to conduct clinical trials. The success of our clinical development programs will
require finding partners to support the clinical development, adequate availability of raw materials and drug product for our research
and development and clinical trials, and, in some cases, may also require the establishment of third-party arrangements to obtain finished
drug product that is manufactured appropriately under good manufacturing practices, and packaged for clinical use or sale. Since we are
a company focused on using our AI/ML technology to advance medicines, any clinical development programs will also require, in all cases,
partners and the establishment of third-party relationships for execution and completion of clinical trials.

Since
completing our initial public offering in February 2023 (the “IPO”), aided by the receipt of the IPO proceeds in addition
to the proceeds from our February 2024 and October 2024 offerings and our ongoing At-The-Market Sales Agreement with BTIG, LLC (the “ATM Agreement”),
we have implemented several initiatives including: investor relations and marketing to raise awareness for the Company in the financial
and business sectors, research and development, collaboration with the J Craig Venter Institute (“JCVI”), and initiation of
preclinical studies with our in-licensed drug programs. The Company is actively engaged in developing and pursuing new intellectual property
as it strives to continuously evolve its AI/ML platform.

Intern